| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3 Signaling Receptor Molecule1
*
Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany;
St. Elisabeth-Krankenhaus Köln-Hohenlind, Köln, Germany; and
Johannes Gutenberg-Universitat, III. Medizinische Klinik, Mainz, Germany
Recombinant immunoreceptors with specificity for the
carcinoembryonic Ag (CEA) can redirect grafted T cells to a
MHC/Ag-independent antitumor response. To analyze receptor-mediated
cellular activation in the context of CD28 costimulation, we generated:
1) CEA+ colorectal tumor cells that express simultaneously
B7-1 and B7-2, and 2) CEA-specific immunoreceptors that harbor
intracellularly the signaling moities either of CD28
(BW431/26-scFv-Fc-CD28), CD3
(BW431/26-scFv-Fc-CD3), or
Fc
RI
(BW431/26-scFv-Fc-). By retroviral gene transfer, we
grafted activated T cells from the peripheral blood with these
immunoreceptors. T cells that express the FcRI or CD3
signaling receptor lysed specifically CEA+ tumor cells and
secreted high amounts of IFN- upon receptor cross-linking, whereas
anti-CEA-CD28 receptor-grafted T cells did not, indicating that
CD28 signaling alone is not sufficient for efficient T cell activation.
CD28 costimulation did not affect cytolysis by T cells equipped with
- or -signaling receptors, but enhanced both IFN- secretion
and proliferation. CD28 costimulation, however, was required for
efficient IL-2 secretion of anti-CEA- receptor-grafted T cells.
Both purified CD4+ and CD8+ T cells grafted
with immunoreceptors required CD28 costimulation for complete T cell
activation. We integrated both CD28 and CD3 signaling domains into
one combined immunoreceptor molecule (BW431/26-scFv-Fc-CD28/CD3)
with dual signaling properties. T cells grafted with the combined
CD28/CD3 signaling receptor secreted high amounts of IL-2 upon Ag
binding without exogenous B7/CD28 costimulation, demonstrating that
both MHC-independent cellular activation and CD28 costimulation for
complete T cell activation can be delivered by one recombinant receptor
molecule.
This article has been cited by other articles:
|
|
 |
|
  K. Dobrenkov, M. Olszewska, Y. Likar, L. Shenker, G. Gunset, S. Cai, N. Pillarsetty, H. Hricak, M. Sadelain, and V. Ponomarev Monitoring the Efficacy of Adoptively Transferred Prostate Cancer-Targeted Human T Lymphocytes with PET and Bioluminescence Imaging J. Nucl. Med., July 1, 2008; 49(7): 1162 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Brentjens, E. Santos, Y. Nikhamin, R. Yeh, M. Matsushita, K. La Perle, A. Quintas-Cardama, S. M. Larson, and M. Sadelain Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts Clin. Cancer Res., September 15, 2007; 13(18): 5426 - 5435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koehler, D. Kofler, A. Hombach, and H. Abken CD28 Costimulation Overcomes Transforming Growth Factor-{beta}-Mediated Repression of Proliferation of Redirected Human CD4+ and CD8+ T Cells in an Antitumor Cell Attack Cancer Res., March 1, 2007; 67(5): 2265 - 2273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Kowolik, M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D. Smith, S. J. Forman, M. C. Jensen, and L. J.N. Cooper CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells. Cancer Res., November 15, 2006; 66(22): 10995 - 11004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Hombach, C Schlimper, E Sievers, S Frank, H H Schild, T Sauerbruch, I G H Schmidt-Wolf, and H Abken A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3{zeta}-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells Gut, August 1, 2006; 55(8): 1156 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Schaft, B. Lankiewicz, J. Drexhage, C. Berrevoets, D. J. Moss, V. Levitsky, M. Bonneville, S. P. Lee, A. J. McMichael, J.-W. Gratama, et al. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFN{gamma} production Int. Immunol., April 1, 2006; 18(4): 591 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. L. Teng, M. H. Kershaw, Y. Hayakawa, L. Cerutti, S. M. Jane, P. K. Darcy, and M. J. Smyth T Cells Gene-engineered with DAP12 Mediate Effector Function in an NKG2D-dependent and Major Histocompatibility Complex-independent Manner J. Biol. Chem., November 18, 2005; 280(46): 38235 - 38241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Moeller, N. M. Haynes, M. H. Kershaw, J. T. Jackson, M. W. L. Teng, S. E. Street, L. Cerutti, S. M. Jane, J. A. Trapani, M. J. Smyth, et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection Blood, November 1, 2005; 106(9): 2995 - 3003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Imai, S. Iwamoto, and D. Campana Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells Blood, July 1, 2005; 106(1): 376 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Willemsen, C. Ronteltap, P. Chames, R. Debets, and R. L. H. Bolhuis T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production J. Immunol., June 15, 2005; 174(12): 7853 - 7858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Friedmann-Morvinski, A. Bendavid, T. Waks, D. Schindler, and Z. Eshhar Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation Blood, April 15, 2005; 105(8): 3087 - 3093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chmielewski, A. Hombach, C. Heuser, G. P. Adams, and H. Abken T Cell Activation by Antibody-Like Immunoreceptors: Increase in Affinity of the Single-Chain Fragment Domain above Threshold Does Not Increase T Cell Activation against Antigen-Positive Target Cells but Decreases Selectivity J. Immunol., December 15, 2004; 173(12): 7647 - 7653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gyobu, T. Tsuji, Y. Suzuki, T. Ohkuri, K. Chamoto, M. Kuroki, H. Miyoshi, Y. Kawarada, H. Katoh, T. Takeshima, et al. Generation and Targeting of Human Tumor-Specific Tc1 and Th1 Cells Transduced with a Lentivirus Containing a Chimeric Immunoglobulin T-Cell Receptor Cancer Res., February 15, 2004; 64(4): 1490 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Finney, A. N. Akbar, and A. D. G. Lawson Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCR{zeta} Chain J. Immunol., January 1, 2004; 172(1): 104 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nguyen, I. Moisini, and T. L. Geiger Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function Blood, December 15, 2003; 102(13): 4320 - 4325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Haynes, J. A. Trapani, M. W. L. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation J. Immunol., November 15, 2002; 169(10): 5780 - 5786. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
